Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO (sulbactam for injection; durlobactam for injection), Co-packaged for Intravenous Use

24.05.2023 - Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced that the U.S. Food and Drug Administration (FDA) approved XACDURO (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use ... Seite 1

Related Keywords

David Altarac ,Drug Administration ,Innoviva Inc ,Nasdaq ,Innoviva Specialty Therapeutics ,Chief Medical Officer ,Innoviva Specialty ,Innoviva ,